We are glad to announce the start of the Chiron project. The aim of the project is to create a smart multi material bioprinting platform for the research and production in the biomedical sector to create a portfolio of biomaterials and applications.
It officially started with the consortium team working on developing the bioprinter. Key milestones being the delivery of the full bioprinting platform to the University of Eindhoven and a special jetting equipment to Trinity College of Dublin. Numerous applications are possible with our technology. This includes: multimaterial biofabrication, personalized medicine & drug discovery, regenerative medicine and bioprocessing, just to name a few. Therefore, we are excited to experience a world where this technology becomes part of scientific research and medicine.
While Chiron is funded by Eurostars, a European programme specifically dedicated to research performing SMEs, Chiron is an international collaboration between two SMEs (Concr3de BV and IPC – Innovative Polymer Compounds) and two research centers (University Medical Center of Utrecht and the Trinity College of Dublin).
PharmaCell is a leading European-based Contract Manufacturing Organization (CMO) exclusively focused in the area of cell therapy and regenerative medicine. PharmaCell has experience in supporting Phase I through Phase III clinical trials and early commercial manufacturing in cell therapy in terms of manufacturing, Quality Control, storage, in-outgoing logistics and product release.
PharmaCell – cell therapy and regenerative medicine CMO
CiMaas BV is a biotech company developing cellular immunotherapy for specific groups of cancer patients. CiMaas focuses on the development of two unique products: a cancer vaccine using the patient’s own immune (dendritic) cells and the production of donor natural killer cells. These methods can help to treat many oncological diseases.